Pelthos CEO to Meet Investors at Piper Sandler Biopharma Symposium
Event summary
- Pelthos Therapeutics CEO Scott Plesha will participate in one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026, in Boston.
- Pelthos is a commercial-stage biopharmaceutical company focused on cutaneous infectious disease treatments.
- The company's lead product, ZELSUVMI™ (berdazimer) topical gel, is the first and only at-home prescription therapy for Molluscum contagiosum.
- Pelthos also markets Xepi® (ozenoxacin) Cream for impetigo and Xeglyze® (abametapir) for head lice.
The big picture
Pelthos Therapeutics is positioning itself as a key player in the dermatology space, focusing on unmet needs in cutaneous infectious diseases. The company's participation in the Piper Sandler Symposium underscores its strategy to engage investors and highlight its differentiated product portfolio. The biopharma sector continues to prioritize innovative treatments for niche dermatological conditions, and Pelthos' focus on at-home therapies could be a significant differentiator.
What we're watching
- Investor Sentiment
- How investor meetings will impact Pelthos' valuation and market positioning.
- Product Differentiation
- Whether Pelthos can sustain competitive advantage with its at-home treatment for Molluscum contagiosum.
- Commercial Strategy
- The pace at which Pelthos expands its portfolio of cutaneous infectious disease treatments.